Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Hyperinsulinemia, glucose intolerance, and dyslipidemia induced by acute inhibition of phosphoinositide 3-kinase signaling in the liver
Kazuaki Miyake, … , Hiroshi Sakaue, Masato Kasuga
Kazuaki Miyake, … , Hiroshi Sakaue, Masato Kasuga
Published November 15, 2002
Citation Information: J Clin Invest. 2002;110(10):1483-1491. https://doi.org/10.1172/JCI15880.
View: Text | PDF
Article Metabolism

Hyperinsulinemia, glucose intolerance, and dyslipidemia induced by acute inhibition of phosphoinositide 3-kinase signaling in the liver

  • Text
  • PDF
Abstract

Research Article

Authors

Kazuaki Miyake, Wataru Ogawa, Michihiro Matsumoto, Takehiro Nakamura, Hiroshi Sakaue, Masato Kasuga

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Expression of Δp85 in the liver of mice injected with an adenoviral vect...
Expression of Δp85 in the liver of mice injected with an adenoviral vector. (a) Time course of the expression of Δp85 in the liver. The liver was removed from mice at the indicated times after injection with AxCAΔp85, or from uninjected animals (day 0), and was subjected to immunoblot analysis (IB) with an mAb specific for bovine p85. (b) Total homogenates of the indicated tissues obtained from mice 3 days after injection with AxCAΔp85 were subjected to immunoblot analysis with the mAb to bovine p85. (c) Liver homogenates prepared from mice 3 days after injection with AxCALacZ or AxCAΔp85 were subjected to immunoblot analysis with polyclonal antibodies that recognize both rodent and bovine p85. Data in a and b are representative of results obtained from three mice; those in c were obtained from four mice for each group.

Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts